IONS

Ionis Pharmaceuticals, Inc.

NasdaqGSUSDEQUITY DELAYED

60.70

▲ 1.94 (3.30%)

MARKET · —

Price

Open

58.76

Prev close

58.76

Day high

60.92

Day low

59.38

Volume

2.63M

Market cap

—

P/E (TTM)

—

52W range

41.71 – 86.74

Trailing performance

Price return · vs SPY

Returnvs SPY

+4.37% +5.7%

+6.93% +3.2%

-21.17% -24.3%

-28.15% -39.2%

YTD

-24.48% -36.8%

+39.55% +19.5%

+51.05% -23.1%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

57.95

+4.74% from price

SMA 20

56.23

+6.23% from price

SMA 50

64.02

-6.68% from price

SMA 100

69.51

-12.68% from price

SMA 200

73.99

-19.26% from price

EMA 12

58.01

+4.63% from price

EMA 26

58.71

+3.39% from price

EMA 50

62.18

-2.38% from price

RSI (14)

52.6

Neutral

MACD (12,26,9)

-0.70

Hist 1.15

ATR (14)

1.87

3.13% of price

Realised vol 30D

35.2%

Annualised

Bollinger upper

60.82

20, 2σ

Bollinger lower

51.65

20, 2σ

50 / 200 cross

Death

64.02 vs 73.99

Trend bias

Below 200

-19.26%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.20

Less volatile than market

Correlation to SPY

0.05

Largely independent

Realised vol 30D

35.2%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-40.2%

Peak to trough

Max drawdown 5Y

-52.4%

Peak to trough

ATR 14

1.87

3.13% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 60.70

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

IONS · links out to the publisher

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 Business Wire · 2d ago RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors GlobeNewswire · 5d ago Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales Simply Wall St. · 6d ago Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain? Simply Wall St. · 7d ago Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? Motley Fool · 8d ago Ionis (IONS) Q2 2026 Earnings Call Transcript Motley Fool · 15d ago Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? Motley Fool · 19d ago Ionis Pharmaceuticals Insider Bought Shares Worth $1,058,700, According to a Recent SEC Filing MT Newswires · 22d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.